Renalytix Ownership
| RNLX Stock | USD 0.16 0.01 6.67% |
Shares in Circulation | First Issued 2018-06-30 | Previous Quarter 97.7 M | Current Value 138.2 M | Avarage Shares Outstanding 52.1 M | Quarterly Volatility 34.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Renalytix |
Renalytix Stock Ownership Analysis
The company recorded a loss per share of 0.62. Renalytix AI had not issued any dividends in recent years. Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York. Renalytix operates under Health Information Services classification in the United States and is traded on NASDAQ Exchange. It employs 51 people. To find out more about Renalytix AI contact the company at 646 397 3970 or learn more at https://renalytix.com.Besides selling stocks to institutional investors, Renalytix also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Renalytix's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Renalytix's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Renalytix Quarterly Liabilities And Stockholders Equity |
|
About 5.0% of Renalytix AI are currently held by insiders. Unlike Renalytix's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Renalytix's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Renalytix's insider trades
Renalytix Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Renalytix is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Renalytix AI backward and forwards among themselves. Renalytix's institutional investor refers to the entity that pools money to purchase Renalytix's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Securities, Llc | 2024-06-30 | 24.7 K | Xtx Topco Ltd | 2024-09-30 | 20.2 K | Lpl Financial Corp | 2024-09-30 | 18.4 K | Ewa, Llc | 2024-06-30 | 16.5 K | Jpmorgan Chase & Co | 2024-06-30 | 16.2 K | Baader Bank Inc | 2024-09-30 | 15 K | Cambridge Invest Research Advisors, Inc. | 2024-09-30 | 14.5 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 12.9 K | Virtu Financial Llc | 2024-06-30 | 12.5 K | Pinnacle Associates Inc | 2024-09-30 | 846.5 K | Stifel Financial Corp | 2024-06-30 | 561 K |
Renalytix AI Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Renalytix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Renalytix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Renalytix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Icahn School Of Medicine At Mount Sinai over three weeks ago Acquisition by Icahn School Of Medicine At Mount Sinai of 13366750 shares of Renalytix at 0.116 subject to Rule 16b-3 | ||
Jung Joel R over three months ago Acquisition by Jung Joel R of 60000 shares of Renalytix at 0.2067 subject to Rule 16b-3 | ||
Jung Joel R over six months ago Insider Trading | ||
Icahn School Of Medicine At Mount Sinai over six months ago Acquisition by Icahn School Of Medicine At Mount Sinai of 9360374 shares of Renalytix at 0.25 subject to Rule 16b-3 | ||
Coste Catherine over a year ago Acquisition by Coste Catherine of 95000 shares of Renalytix subject to Rule 16b-3 | ||
Mclain Thomas H over a year ago Acquisition by Mclain Thomas H of 200000 shares of Renalytix subject to Rule 16b-3 |
Renalytix Outstanding Bonds
Renalytix issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Renalytix AI uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Renalytix bonds can be classified according to their maturity, which is the date when Renalytix AI has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| NECELE 217 25 NOV 26 Corp BondUS75972BAB71 | View | |
| RENAISSANCERE FIN INC Corp BondUS75973QAA58 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| RENIASSANCERE FIN INC Corp BondUS75972YAA91 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Renalytix Stock Analysis
When running Renalytix's price analysis, check to measure Renalytix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Renalytix is operating at the current time. Most of Renalytix's value examination focuses on studying past and present price action to predict the probability of Renalytix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Renalytix's price. Additionally, you may evaluate how the addition of Renalytix to your portfolios can decrease your overall portfolio volatility.